This content is intended for healthcare professionals only and is not intended for the general public. This content is funded by Galderma SA. Please refer to the prescribing information applicable in your country of practice.
Podcast 1: IL-31 Modulation of Inflammation, Epidermal Dysregulation, Itch, and Fibrosis in Atopic Dermatitis (AD) and Prurigo Nodularis (PN) lesions
- The role of IL-31 driving fibrosis and epidermal dysregulation in AD and PN
- IL-31 as a key proinflammatory cytokine and a neuromodulator of itch
Podcast 2: OLYMPIA Long-Term Extension Results of Nemolizumab in Prurigo Nodularis Phase III Study at Week 100
- Outcomes from the OLYMPIA two-year Long-Term Extension (LTE) trial of nemolizumab in PN
- Implications of trial results for real-world clinical practice
In this two-part EMJ video podcast series, four leading experts discuss the various roles IL-31 plays in inflammation, barrier control, itch and fibrosis PN and AD, as well as the LTE data of OLYMPIA 1 and 2 trials in PN.
Nemolizumab (Nemluvio®) is approved in the European Union for the treatment of moderate-to-severe atopic dermatitis in patients (≥12 years) and moderate-to-severe prurigo nodularis in adults who are candidates for systemic therapy. Please refer to local prescribing information for complete safety and prescribing information.
Speakers
Sarina Elmariah1
Maxwell Sauder2
Matthias Augustin3
Andrew Pink4
1. Professor of Clinical Dermatology, University of California, San Francisco (UCSF); Director, UCSF Center for Itch and Neurosensory Disorders, USA
2. Professor of Dermatology, University of Toronto, Canada
3. Professor of Dermatology, University Medical Center Hamburg-Eppendorf; Director, Institute for Health Services Research in Dermatology and Nursing (IVDP), Hamburg, Germany
4. Consultant Dermatologist, St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
